AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Phathom Pharmaceuticals to present at investor conferences in September.
ByAinvest
Monday, Aug 25, 2025 8:03 am ET1min read
Phathom Pharmaceuticals has announced that management team members will participate in investor conferences in September. The events include the Cantor Global Healthcare Conference 2025 in New York from September 3-5 and the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10. The conferences will feature 1x1 meetings and live webcasts, accessible on the Phathom website.
Phathom Pharmaceuticals (NASDAQ: PHAT) has announced that its management team will participate in two upcoming investor conferences in September 2025. The events include the Cantor Global Healthcare Conference 2025 in New York from September 3-5 and the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10. Both conferences will feature one-on-one meetings and live webcasts, accessible on the Phathom website.At the Cantor Global Healthcare Conference 2025, scheduled for September 3-5, Phathom's management team will participate in one-on-one meetings throughout the conference. The live webcast of the event will be available on the Phathom website. For those unable to attend, the webcast will be archived for up to 90 days following the conclusion of the event [1].
The H.C. Wainwright 27th Annual Global Investment Conference, taking place from September 8-10, will also feature Phathom's management team, who will participate in one-on-one meetings. The live webcast of this event will be available on the Phathom website as well. The webcast will be archived for up to 90 days following the conclusion of the event [1].
Phathom Pharmaceuticals focuses on developing and commercializing novel treatments for gastrointestinal diseases. The company markets VOQUEZNA®, a first-in-class potassium-competitive acid blocker (PCAB) for various gastrointestinal conditions including Non-Erosive GERD and H. pylori infection treatment [1].
References:
[1] https://www.stocktitan.net/news/PHAT/phathom-pharmaceuticals-to-participate-in-upcoming-investor-nnibl7okihup.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet